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Abstract
Diabetes mellitus is the most common endocrine disorder, causes many complications 
such as micro- and macro-vascular diseases. Anti-diabetic, hypolipidemic and anti-oxidative 
properties of ginger have been noticed in several researches. The present study was conducted 
to investigate the effects of ginger on fasting blood sugar, Hemoglobin A1c, apolipoprotein 
B, apolipoprotein A-I, and malondialdehyde in type 2 diabetic patients. In a randomized, 
double-blind, placebo-controlled, clinical trial, a total of 41 type 2 diabetic patients randomly 
were assigned to ginger or placebo groups (22 in ginger group and 19 in control group), 
received 2 g/day of ginger powder supplement or lactose as placebo for 12 weeks. The serum 
concentrations of fasting blood sugar, Hemoglobin A1c, apolipoprotein B, apolipoprotein A-I 
and malondialdehyde were analyzed before and after the intervention. Ginger supplementation 
significantly reduced the levels of fasting blood sugar, hemoglobin A1c, apolipoprotein B, 
apolipoprotein B/apolipoprotein A-I and malondialdehyde in ginger group in comparison to 
baseline, as well as control group, while it increased the level of apolipoprotein A-I (p<0.05). It 
seems that oral administration of ginger powder supplement can improves fasting blood sugar, 
hemoglobin A1c, apolipoprotein B, apolipoprotein A-I, apolipoprotein B/apolipoprotein A-I 
and malondialdehyde in type 2 diabetic patients. So it may have a role in alleviating the risk of 
some chronic complications of diabetes. 
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Introduction
Diabetes mellitus can be defined as a group 
of metabolic diseases characterized by chronic 
hyperglycemia resulting from impaired insulin 
action/secretion and is classified into two major 
categories, type 1 and type 2. Type 2 diabetes 
accounts for >90% of diabetes and is resulting 
in impaired function in carbohydrate, lipid 
and protein metabolism. Effective control of 
hyperglycemia in diabetic patients is critical for 
reducing the risk of micro- and macro-vascular 
diseases (1). 
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and it is one of the most widely consumed spices 
worldwide. It has a long history of use as herbal 
medicine to treat a variety of diseases including 
nausea and vomiting, constipation, indigestion 
(dyspepsia), pain, and cold induced syndromes. 
More recently, it was reported that ginger 
also possesses anti-cancer, anti-clotting, anti-
inflammatory, and anti-oxidative characteristics, 
since it can scavenge superoxide anion and 
hydroxyl radicals (2). 
Ginger is known to contain a number 
of potentially bioactive substances, mainly 
gingerols and their related dehydration products, 
the shogaols, as well as volatile oils including 
sesquiterpenes, such as beta-bisabolene and 
(-)-zingiberene, and monoterpenes, mainly 
geranial and neral (9). In addition, phytochemical 
reports have shown that the main constituents 
of ginger are gingerol, shogaol, zingerone and 
paradol. It was reported that 6-gingerol and 
6-shogaol are the major gingerol and shogaol 
present in the rhizome (1). 
Ginger has been shown to possess anti-
diabetic activity in a variety of studies. Akhani 
et al. (2004) reported that ginger pretreatment 
inhibited the induced hyperglycemia and 
hypoinsulinemia (10). Other investigators have 
showed the hypolipidemic effect of ginger 
(11). Other studies suggested that the response 
to ginger components depends on it᾽s dose 
concentration (12, 13). Some experimental 
researches published on anti-diabetic, hypo-
lipidemic and anti-oxidative properties of ginger 
are controversial and more investigations may 
clarify it᾽s potency in protection and treatment 
of metabolic disorders (6).
Therefore, the present study was planned 
to evaluate the effects of ginger powder 
supplementation on serum levels of fasting 
blood sugar (FBS), Hemoglobin A1c (HbA1c), 
apolipoprotein B (apo B), apolipoprotein A-I 
(apo A-I), Apo B/Apo A-I, and malondialdehyde 
(MDA) in type 2 diabetic patients.
Experimental
Materials and methods
The present study was a randomized, double 
blind, placebo controlled clinical trial performed 
on type 2 diabetic patients. The population 
The prevalence of diabetes mellitus has 
reached epidemic proportions and has affected 
6.4% of adults worldwide in 2010 (2). The global 
prevalence for all age groups was estimated to 
be 4.4% in 2030 (3). The number of patients 
suffering from diabetes, among the 25-64 years 
old Iranians is 7.7%, equal to 2 million patients, 
which half of them are not aware of their disease. 
As well as, 6.8%, equal to 4.4 million of Iranian 
adults have impaired fasting glucose (4).   
Dyslipidemia (lipid abnormalities) resulting 
from uncontrolled hyperglycemia and insulin 
resistance in diabetic patients is a major risk 
factor for coronary artery disease, stroke and 
peripheral vascular disease (5). 
Recently, attention has been focused on the 
relationship between production of free radicals, 
especially reactive oxygen species (ROS), 
and the pathogenesis as well as progression of 
diabetes mellitus. Mechanisms that contribute to 
the formation of free radicals in diabetes mellitus 
may include metabolic stress resulting from 
changes in energy metabolism, inflammatory 
mediators and impaired antioxidant defense 
mechanisms (5). Hyperglycemia increases 
oxidative stress through the overproduction 
of reactive oxygen species, which results in 
an imbalance between free radicals and the 
antioxidant defense system of the cells (3). It 
was reported that oxidative stress which affects 
carbohydrate, lipid and protein metabolism (3), 
increase in patients with diabetes mellitus and 
suggested to induce endothelial cell dysfunction 
and trigger the progression of atherosclerosis (6). 
The elevated blood glucose levels in diabetes are 
thought to lead to cell death through oxidative 
stress induction (3). Because of the increased 
risk of cardiovascular disease in these patients, 
the preventive strategy of normal blood lipids 
and reduction of oxidative stress should be 
considered.  
Apart from conventional anti diabetic therapy, 
medicinal plants, complementary and alternative 
medicine therapies have beneficial effects and 
improve glucose homeostasis in diabetic patients 
(7). Several ethno pharmacological studies 
on medicinal plants having beneficial effects 
on diabetes have been reported (8). Ginger 
is an underground rhizome of plant Zingiber 
officinale belonging to the family  Zingiberaceae 
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of the study included all adult patients, aged 
20-60 years old, who were referred to the Iran 
diabetes association in Tehran. The under 
study patients were diagnosed with non insulin 
dependent diabetes mellitus (NIDDM) by an 
endocrinologist on the basis of the results of 
the blood tests and met the criteria of the study. 
These criteria included: disease duration at 
least 2 years, HbA1c level of 6-8%, taking no 
antioxidant supplements such as selenium, zinc 
and beta-carotene for at least 3 months prior to 
the study, no smoking and drinking. Exclusion 
criteria of the study were insulin therapy at 
baseline or during the study, changes in the 
type or dose of medication, changes in diet or 
daily physical activity, any acute illnesses or 
some chronic diseases including kidney, liver, 
cardiovascular, and gastrointestinal diseases, 
smoking, pregnancy and lactation, consumption 
of ginger or other botanical supplements, ginger 
hypersensitivity, and consumption of less than 
80% of supplements during the study period.
Sample size was determined based on data 
from previous study (14) by considering type I 
error level α=0.05 with test power of 80%. To 
insure that the sample size, used in the study, 
could obtain the desired outcome for all relevant 
variables, the highest number of the calculated 
samples was considered. The sample size was 
computed as 20 per group. Regarding a possible 
loss to follow-up, a safety margin of 25% was 
determined, and therefore 25 patients were 
allocated in each group.
After attending the orientation session and 
fulfilling written informed consent paper, the 
participants were enrolled, and 50 eligible 
patients of either sex included in the study. 
Patients were divided randomly into two 
groups (experiment and control, 25 subjects 
in each) using computer᾽s random numbers to 
receive either ginger or placebo one capsule 
twice a day for 12 weeks (15). All subjects were 
permitted to consume their usual medications 
according to their physician᾽s recommendation. 
At the beginning of the study, information 
on socio-economic status of participants was 
collected by means of a questionnaire completed 
through an interview. The report of daily dietary 
intake was collected by a 24-hour diet recall 
questionnaire once at the beginning and at the 
end of the study. The data was then analyzed by 
Nutritionist IV software. The reports of the level 
of physical activity, at the beginning and the end 
of the study, were obtained through interview 
with individuals using the International Physical 
Activity Questionnaire (IPAQ). The patients 
were instructed to maintain their diet and 
physical activity during the intervention. 
Anthropometric parameters including height 
and weight were measured at the beginning and 
the end of the intervention to calculate body 
mass index (BMI) as the formula (weight (Kg)/
height squared (m2)). Body weight was measured 
without shoes and light clothing by using a seca 
scale with the precision of 0.5 Kg. Heights were 
also measured using a stadiometer without shoes 
with precision of 0.5 cm. During the 12-week 
intervention practice, the patients were called 
to resolve possible problems and ensure that 
the participants had consumed the drugs and 
supplements. 
Blood samples (10 mL) were taken in a 10-12 
hours fasting state at the beginning and after 12 
weeks of intervention. The serum was obtained 
by high speed centrifugation and was frozen 
immediately at −80 °C until assay. 
The concentration of FBS was measured by 
enzymatic method using eliteh kit (via Hitachi 
machine) from French company of Feppim 
717. Measurement of serum HbA1c level 
was performed by turbidometric inhibition 
immunoassay method using Roche kit from 
Germany. Apo B and apo A-I were also assayed 
by turbidometric immunoassay method using 
Roche kits (via Cobas machine) from Germany. 
Serum level of MDA was calculated by 
spectrophotometry method (Satoh 1978) (16) 
according to the instruction.
Fresh rhizomes of Zingiber officinale were 
purchased from local market and were ground 
as a fine particle after drying. The powder 
was delivered to a pharmaceutical lab (Tehran 
university of medical sciences, Iran) to prepare 
capsules containing 1 gram ginger in each (17). 
Lactose was also used to make placebo (18). The 
capsules were placed in the identical bottles by 
a third person not directly involved in this study. 
This person labeled the bottles with 2 cods 
which retained unknown for researchers and 
patients until the end of intervention. To evaluate 
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the compliance of patients, bottles containing 
unconsumed ginger (or placebo) capsules 
were given monthly, and if was >20% of total 
delivered supplements the patient was excluded 
from the intervention.
The data were analyzed by SPSS software 
(version 16) and the results were expressed 
as mean ± standard deviation (Mean ± SD). 
The normality of the distribution of variables 
was determined by the Kolmogorov-Smirnov 
test. The differences in the levels of blood 
biochemical variables were compared, before 
and after the intervention, in each group. For 
variables with normal distribution, a paired t-test 
and for variables other than those, a wilcoxon 
test was used. To compare quantitative variables 
between the two groups, independent t-test and 
Mann-withney test were used for normal and 
non normal distribution variables, respectively. 
Differences with p-value <0.05 were considered 
to be statistically significant.  
The protocol of study was in compliance 
with the Helsinki Convention of 1975 (revised in 
2008) and informed consent form was obtained 
from each patient. The study was approved by 
the Ethics Committee of Public Health School 
of Tehran University of Medical Sciences (No. 
2402), and registered in Iranian center of clinical 
trial registration with the ID number of IRCT 
201109082709N19.
Results  
Of 50 patients initially recruited, 41 persons 
(22 in the ginger group and 19 in the control 
group) completed the study, and 9 persons were 
excluded because of migration, change in type 
and dose of medication, and refusing to continue. 
There were 5 males and 17 females in the ginger 
group with an average age of 45.20 ± 7.64 years 
old and 9 males and 10 females with an average 
age of 47.10 ± 8.31 years in the control group.
There were no significant differences between 
the intervention and control groups regarding 
the distribution of sex, age, weight, waist 
circumference, body mass index (BMI), disease 
duration, type of consumed oral hypoglycemic 
drugs, daily dietary intake and the level of 
physical activity, at the beginning and the end of 
the study (p>0.05).
The table showed that there were no 
statistically significant differences in the baseline 
levels of FBS, HbA1c, Apo B, Apo A-I and Apo 
B/Apo A-I between the ginger and placebo 
groups (p>0.05), while the level of MDA was 
statistically different (p = 0.014). 
Ginger supplementation significantly reduced 
the levels of FBS (p=0.000), HbA1c (p=0.000), 
Apo B (p=0.000), Apo B/Apo A-I (p=0.000) 
and MDA (p=0.001), as well as increased the 
level of Apo A-I (p=0.000) in the ginger group 
in comparison to the baseline. While the levels 
of FBS (p=0.048), Apo B (p=0.000), Apo B/Apo 
A-I (p=0.000) and MDA (p=0.004) increased, 
and Apo A-I (p=0.008) reduced in placebo group 
during the study. However, the statistical analysis 
indicated that the observed changes in control 
group may be the result of time effect, placebo 
empathic effect or other unknown factors, and 
it᾽s not intervention dependent (Table 1). 
As well as, results exhibited statistically 
significant differences in mean difference values 
of FBS, HbA1c, Apo B, Apo A-I, Apo B/Apo 
A-I and MDA (p=0.0000) between two groups 
at the end of study (Table 1).
Discussion
The present study was conducted to 
investigate the effects of ginger on fasting 
blood sugar (FBS), Hemoglobin A1c (HbA1c), 
apolipoprotein B (Apo B), apolipoprotein A-I 
(Apo A-I), Apo B/Apo AI, and malondialdehyde 
(MDA) in type 2 diabetic patients.
In this study, it was demonstrated that oral 
administration of ginger powder for 12 weeks at 
dose of 2 g per day caused significant reduction 
in the levels of FBS, HbA1c, Apo B, Apo B/Apo 
A-I and MDA in ginger group in comparison 
to baseline, as well as control group, while it 
increased the level of Apo A-I.
Ojewole J.A.O. (2006) reported that oral 
intake of alcoholic extract of ginger (800 mg/
Kg) significantly decreased the level of fasting 
blood sugar after 1 hour treatment in STZ-
diabetic rats. The effect peak was observed after 
4 hours and 24-53% reduction of blood glucose 
with consumption of doses of 100-800 mg/Kg 
(19). As well as, Islam M.S. & Choi H (2008), in 
nicotinamide and low dose STZ-diabetic rat 
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Figure 1. The consort flowchart describing the progress of the patients through the trial.
model, noticed that oral administration of ginger 
powder at dose of 200 mg/Kg resulted in 
alleviation of metabolic syndrome signs 
including blood glucose and serum lipids 
reduction and increasing total antioxidant 
capacity (TAC) (20). Our results are similar to 
these results. However, Bordia A. et al. (1997) 
stated that the consumption of 4 g/day ginger 
powder in coronary artery disease (CAD) 
duration 3 months did not change the level of 
serum glucose and lipids (21). The differences in 
our results with this study may be due to 
difference in chemical composition of 
administered ginger extract, preparation method, 
rhizome used, or storage time (22,23). Jafri SA. 
et al. (2011) showed that oral administration of 
ginger extract with daily dose of 500 mg/Kg for 
6 weeks in Alloxan-diabetic rats caused 
decreased in blood glucose level at 21 and 42 
days (24). Abdulrazaq NB. et al. (2010) in a 
study found that daily administration of oral 
ginger aqueous at dose of 500 mg/Kg during 30 
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days in STZ-diabetic rats caused 38% and 68% 
reduction in plasma glucose level, on the 15th 
and 30th day of study, respectively. This solution 
have hypoglycemic effect by increased the 
activity of glycolytic enzymes (glucokinase, 
phosphofructokinase, pyruvate kinase) (25). 
Another study performed by Saeid JM. et al. 
(2010) indicated that administration of oral 
ginger extract in diabetic chickens for 6 weeks 
led to decreased the serum levels of glucose, 
triglyceride (TG), total cholesterol (TC), and 
LDL-C, and increased serum HDL-C level (26). 
Apo A-I as the main apolipoprotein of HDL 
structure is the serum level representative of 
HDL-C. Several studies found a strong 
relationship between the elevation of plasma 
HDL-C and Apo A-I, the change in plasma Apo 
A-I concentration explaining almost half 
(approximately 48%) of the variation in HDL-C 
concentration during the course of the 
intervention. This relationship could either 
reflect a decrease in the clearance of HDL-C 
particles and/or an increase in the synthesis of 
Apo A-I during the course of the intervention. As 
well as, apo B as the main apolipoprotein of 
LDL structure, is the serum level representative 
of LDL-C, and decrease of Apo B in this study 
means that small, dense LDL was significantly 
less than control group. However, apo B and apo 
A-I were better than LDL-C and HDL-C, 
respectively, in predicting cardiovascular risk in 
type 2 diabetes (27). Khadem Ansari MH. et al. 
variable time
Groups
p-value*Ginger
(n=22)
Placebo
(n=19)
FBS
(mg/dl)
Before intervention 161.50 ± 58.01 155.47 ± 81.83 0.785
After intervention 142.09 ± 47.90 157.10 ± 81.83 0.875
Difference -19.41 ± 18.83 1.63 ± 4.28 0.000
p-value** 0.000 0.048 _
HbA1c
(%)
Before intervention 7.37 ± 1.86 7.30 ± 1.31 0.619
After intervention 6.60 ± 1.26 7.32 ± 1.32 0.083
Difference -0.77 ± 0.88 0.02 ± 0.16 0.000
p-value** 0.000 0.513 _
Apo B
(mg/dl)
Before intervention 92.95 ± 39.44 89.21 ± 20.67 0.701
After intervention 80.50 ± 36.69 90.07 ± 20.48 0.302
Difference -12.45 ± 10.57 0.86 ± 0.57 0.000
p-value** 0.000 0.000 _
Apo A-I
(mg/dl)
Before intervention 141.36 ± 68.43 119.55 ± 3.73 0.431
After intervention 161.91 ± 71.73 118.85 ± 3.89 0.001
Difference 20.54 ± 14.74 -0.70 ± 1.23 0.000
p-value** 0.000 0.008 _
Apo B/Apo A-I
(mg/dl)
Before intervention 0.72 ± 0.29 0.75 ± 0.18 0.719
After intervention 0.52 ± 0.17 0.76 ± 0.17 0.000
Difference -0.20 ± 0.16 0.01 ± 0.01 0.000
p-value** 0.000 0.000 _
MDA
(nmol/mL)
Before intervention 3.75 ± 1.38 2.89 ± 0.66 0.014
After intervention 2.90 ± 0.98 2.95 ± 0.69 0.637
Difference -0.85 ± 1.08 0.06 ± 0.08 0.000
p-value** 0.001 0.004 _
* independent t-test for normal distribution variables, and Mann-Withney test for non-normal distribution variables 
** paired t-test for normal distribution variables, and wilcoxon test for non-normal distribution variables 
Table 1. The mean and standard deviation (Mean ± SD) of blood biochemical variables at the beginning and the end of the study.
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(2008) found blood glucose concentration have 
more decreased in STZ-diabetic rats treated with 
ginger powder (5% of daily dietary intake for 6 
weeks) compared to control diabetic rats. The 
HbAlc level in the ginger-treated group was 
significantly lower than that in the non treated 
diabetic group. It has been showed that HbAlc 
level is increased during diabetes and it is a 
marker which shows the degree of protein 
glycation. Administration of ginger to diabetic 
rats significantly decreased the level of 
glycosylated hemoglobin and this may be due to 
the decreased level of blood glucose (28). Our 
results are in agreement with these results. Many 
investigators reported that compounds of ginger 
such as 6-gingerol, tannins, polyphenolic 
compounds, flavonoids, and triterpenoids 
possess hypoglycemic and other pharmacological 
properties (3). Rani MP. et al. (2010) suggested 
that ginger, via it᾽s major component, gingerol, 
by inhibition of key enzymes relevant to type 2 
diabetes, α-glucosidase and α-amylase, are 
known to improve diabetes (29). Li Y. et al. 
(2012) found that polar portion of ginger extract 
containing mainly gingerols, particularly (S)-
[6]- and (S)-[8]- gingerol, promoted glucose 
uptake significantly in cultured rat skeletal 
muscle cells. This action of gingerols was 
attributed to facilitation of insulin-independent 
glucose uptake by increasing translocation of 
glucose transporter GLUT4 to the muscle cell 
plasma membrane surface, together with small 
increases in total GLUT4 protein expression (1). 
Another mechanism for reducing blood glucose 
by ginger hydroalcoholic extract, is the inhibition 
of hepatic phosphorylase enzyme, hereby it 
prevents the breakdown of hepatic glycogen 
storages, also, can increases the activity of 
enzymes improving glycogen synthesis. The 
other possible effect is suppression the activity 
of hepatic «glucose 6-phosphatase» enzyme, 
that causes degradation of glucose 6-phosphate 
to glucose, and consequently increases blood 
glucose level (30). In-vitro studies suggested 
that ethyl acetate extract of ginger have inhibitory 
effect on the two key enzymes of glucose 
metabolism (α-amylase and α-glucosidase); the 
function of ginger against these two enzymes 
was found to be correlated with phenolic content 
of gingerol and shogaol at these extracts. Ginger 
has been shown to modulate insulin release. 
Ginger promotes glucose clearances in insulin 
responsive peripheral tissues, which is crucial in 
maintaining blood glucose homeostasis (29). As 
well as, it is reported that 6-gingerol increases 
the glucose uptake at insulin responsive 
adipocytes (31). Thus, at treated cells with 
gingerol, insulin responsive glucose uptake has 
increased and improved diabetes (30). Several 
studies stated that ginger have permanent effects 
of reducing lipids, and accordingly, increases 
insulin sensitivity. Owing to some studies 
showed that increasing the level of plasma free 
fatty acids (FFAs) lead to insulin resistance, 
ginger indicate anti-insulin resistance effects by 
reducing the level of plasma FFAs (32). Elshater 
A.A.E. et al. (2009) indicated that daily oral 
administration of ginger extract (4 mg/Kg) to 
STZ-diabetic rats resulted in reducing the plasma 
level of glucose, total cholesterol, LDL-C, and 
increasing HDL-C, comparing to control rats 
(2). The hypocholesterolemic effects of ginger 
may be due to the inhibition of cellular cholesterol 
synthesis, since, ((E)-8 beta, 17-epoxyllabed-12-
ene-15, 16 dial) compound was isolated from 
ginger and interfered with cholesterol 
biosynthesis in liver homogenate in 
hypercholesterolemic mice causing it᾽s reduction 
(33). Shanmugam K.R. et al. (2009) noticed that 
feeding with a diet containing 1% and 2% ginger 
powder during 30 days period decreased serum 
level of glucose and malondialdehyde (MDA) in 
STZ-diabetic rats, while it didn’t influence in 
normal rats (3). Moreover, Madkor H.R. et al. 
(2011) indicated that addition of ginger (1%) to 
a normal diet prevented the formation of free 
radicals and maintained the integrity of rat 
erythrocytes. The antioxidant potency of ginger 
has been attributed to gingerols that prevent 
reactive oxygen species (ROS) production (5). 
More than 50 antioxidants have been isolated 
from ginger rhizome; these antioxidants include 
two groups of components related to gingerols 
and diarylheptanoids (34). The major pungent 
component of ginger is gingerol, a mixture of 
homologues with 10, 12 and 14 carbons in the 
side chain designated (6)- (8)- and (10)-gingerols. 
Gingerols can be converted to shogoals and 
zingerone by dehydration and retro-aldol 
reaction, respectively (7). In one study, ginger 
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extract consumption inhibited LDL oxidation in 
apolipoprotein-E deficient mice; this could be 
due to direct ability of ginger extract in 
scavenging free radicals (35). Harliansyah A.H. 
et al. (2005) indicated that the treatment of 
human normal liver cells and liver cancer cells 
with 500 µg/mL of ginger extract, in-vitro, didn’t 
change the content of malondialdehyde (MDA); 
our findings are inconsistent with these findings. 
However, ginger contains three main compounds 
of gingerol, shogaol, and paradol, which exhibit 
antioxidant activity (36). Al-Azhary D.B. (2011) 
stated that oral administration of ginger extract 
with daily dose of 25 mg/Kg for 6 weeks in STZ-
diabetic rats, according to our finding, caused 
significant reduction in blood glucose, 
triglyceride, and malondialdehyde, and 
increasing in plasma total antioxidant capacity 
(TAC), while it couldn’t return increased total 
cholesterol and LDL-C to normal level. Ginger 
has been reported to have a lowering effect on 
lipid peroxidation, thus MDA level, by 
influencing the enzymatic blood level of 
superoxide dismutase (SOD), catalase (CAT), 
and glutathione peroxidase (GPX). It has been 
also shown that ginger reduces cellular oxidation 
and scavenges superoxide anion and hydroxyl 
radicals (6). Lebda M.A. et al. (2012) suggested 
that intake of different forms of ginger (powder, 
warm or cold extract) in amount 2% of basal diet 
in rabbits resulted in significant decline in serum 
level of TG, TC, LDL-C, MDA, while it 
increased the level of blood glucose and HDL-C. 
Reduction of lipid peroxidation by ginger has 
been attributed to it᾽s antioxidant activity, 
because ginger have many phenolic compounds, 
which have inhibitory effects on lipid 
peroxidation and preserve the antioxidant 
compounds (33). The basic concentration of the 
serum glucose of the rabbits in that study was 
lower than that of our study patients, the rabbits 
were not diabetic; as well as, the comparison 
between that study findings with our finding was 
impossible, because it may be different the 
glucose metabolism in humans and rabbits body. 
In conclusion, the present study showed that 
ginger supplementation significantly reduced the 
levels of FBS, HbA1c, Apo B, Apo B/Apo A-I 
and MDA, and increased the level of Apo A-I 
in type 2 diabetic patients. Regarding negligible 
side effects of ginger, it may be a good remedy 
for diabetic patients to diminish the risk of some 
secondary chronic complications. 
The present study was the first human 
research investigating the effects of ginger on 
glycemic status and stress oxidative in type 2 
diabetic patients whose information regarding 
potential confounding variables, including 
dietary intake and physical activity level were 
available. However, this study had limitations, 
as well. First, several patients participating in 
the intervention, were excluded from the study. 
Moreover, frequent inclusion criteria, especially 
having no metabolic diseases and taking no 
antioxidant supplements, led to further reduction 
in the number of patients eligible for the study 
and hampered the disease finding process with 
many difficulties.
Finally, it is suggested to perform similar 
studies with higher number of patients and 
longer study period for a better observation 
of the effects of ginger in improving diabetic 
patient status.
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